Evidence map›Paper›PMID 37152485›Full record

ArticleAdvances in radiation oncology

Clinicopathologic Factors and Their Association with Outcomes of Salivary Duct Carcinoma: A Multicenter Experience.

Brady S Laughlin, Sasha Ebrahimi, Molly M Voss, Samir H Patel, Robert L Foote, Lisa A McGee, Joaquin Garcia, Daniel J Ma, Yolanda I Garces, Michelle A Neben Wittich and 9 more

Open access · goldAbstract read
In one paragraph

Article in Advances in radiation oncology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 6 institutions in 1 country.

Brady S LaughlinDepartment of Radiation Oncology, Mayo Clinic, Phoenix, Arizona.
Sasha EbrahimiTransitional Year Residency Program, Riverside Community Hospital, Riverside, California.
Molly M VossDepartment of Quantitative Health Sciences, Mayo Clinic, Scottsdale, Arizona.
Samir H PatelDepartment of Radiation Oncology, Mayo Clinic, Phoenix, Arizona.
Robert L FooteDepartment of Radiation Oncology, Mayo Clinic, Rochester, Minnesota.
Lisa A McGeeDepartment of Radiation Oncology, Mayo Clinic, Phoenix, Arizona.
Joaquin GarciaDepartment of Lab Medicine and Pathology, Mayo Clinic, Rochester, Minnesota.
Daniel J MaDepartment of Radiation Oncology, Mayo Clinic, Rochester, Minnesota.
Yolanda I GarcesDepartment of Radiation Oncology, Mayo Clinic, Rochester, Minnesota.
Michelle A Neben WittichDepartment of Radiation Oncology, Mayo Clinic, Rochester, Minnesota.
Katharine A PriceDepartment of Hematology and Oncology, Mayo Clinic, Rochester, Minnesota.
Alessandra SchmittDepartment of Lab Medicine and Pathology, Mayo Clinic, Phoenix, Arizona.
Qihui ZhaiDepartment of Lab Medicine and Pathology, Mayo Clinic, Phoenix, Arizona.
Byron C MayDepartment of Radiation Oncology, Mayo Clinic, Jacksonville, Florida.
Thomas H NagelDepartment of Otorhinolaryngology, Mayo Clinic, Phoenix, Arizona.
Michael L HinniDepartment of Otorhinolaryngology, Mayo Clinic, Phoenix, Arizona.
Ashish V ChintakuntlawarDepartment of Hematology and Oncology, Mayo Clinic, Phoenix, Arizona.
Todd A DeWeesDepartment of Quantitative Health Sciences, Mayo Clinic, Scottsdale, Arizona.
Jean-Claude M RwigemaDepartment of Radiation Oncology, Mayo Clinic, Phoenix, Arizona.
Mayo Clinic · USMayo Clinic in Florida · USWinnMed · USMayo Clinic Hospital · USMayo Clinic in Arizona · USRiverside Community Hospital · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: This series reports long-term clinical outcomes of patients with salivary duct carcinoma (SDC), which is associated with a poor prognosis. Methods and Materials: Eighty-nine patients with SDC were treated with curative intent from February 5, 1971, through September 15, 2018. Kaplan-Meier and competing risk analyses were used to estimate locoregional control, distant metastasis-free survival (DMFS), progression-free survival, and overall survival (OS). Cox regression analyses of disease and treatment characteristics were performed to discover predictors of locoregional control, DMFS, and OS. Results: Median follow-up was 44.1 months (range, 0.23-356.67). The median age at diagnosis was 66 years (interquartile range, 57-75). Curative surgery followed by adjuvant radiation therapy was performed in 73 patients (82%). Chemotherapy was delivered in 26 patients (29.2%). The 5-year local recurrence and distant metastasis rates were 27% and 44%, respectively, with death as a competing risk. Distant metastasis was associated with lymph node-positive disease (hazard ratio [HR], 3.16; 95% confidence interval [CI], 1.38-7.23; Conclusions: In this single-institution, multicenter retrospective study, the 5-year survival was 42% in patients with SDC. Lymphovascular space invasion, lymph node involvement, and higher staging at diagnosis were associated with lower DMFS and OS.

Identifiers

PMID37152485
PMCPMC10157113
OpenAlexW4322743593

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.